Frankie Lam
Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
Lam, Frankie; Abbas, Abdullahi Y.; Shao, Hao; Teo, Theodosia; Adams, Julian; Li, Peng; Bradshaw, Tracey D.; Fischer, Peter; Walsby, Elisabeth; Pepper, Chris; Chen, Yi; Ding, Jian; Wang, Shudong
Authors
Abdullahi Y. Abbas
Hao Shao
Theodosia Teo
Julian Adams
Peng Li
Dr TRACEY BRADSHAW tracey.bradshaw@nottingham.ac.uk
Associate Professor
Peter Fischer
Elisabeth Walsby
Chris Pepper
Yi Chen
Jian Ding
Shudong Wang
Abstract
Dysregulation of cellular transcription and translation is a fundamental hallmark of cancer. As CDK9 and Mnks play pivotal roles in the regulation of RNA transcription and protein synthesis, respectively, they are important targets for drug development. We herein report the cellular mechanism of a novel CDK9 inhibitor CDKI-73 in an ovarian cancer cell line (A2780). We also used shRNA-mediated CDK9 knockdown to investigate the importance of CDK9 in the maintenance of A2780 cells. This study revealed that CDKI-73 rapidly inhibited cellular CDK9 kinase activity and down-regulated the RNAPII phosphorylation. This subsequently caused a decrease in the eIF4E phosphorylation by blocking Mnk1 kinase activity. Consistently, CDK9 shRNA was also found to down-regulate the Mnk1 expression. Both CDKI-73 and CDK9 shRNA decreased anti-apoptotic proteins Mcl-1 and Bcl-2 and induced apoptosis. The study confirmed that CDK9 is required for cell survival and that ovarian cancer may be susceptible to CDK9 inhibition strategy. The data also implied a role of CDK9 in eIF4E-mediated translational control, suggesting that CDK9 may have important implication in the Mnk-eIF4E axis, the key determinants of PI3K/Akt/mTOR- and Ras/Raf/MAPK-mediated tumorigenic activity. As such, CDK9 inhibitor drug candidate CDKI-73 should have a major impact on these pathways in human cancers.
Citation
Lam, F., Abbas, A. Y., Shao, H., Teo, T., Adams, J., Li, P., …Wang, S. (2014). Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget, 5(17), 7691–7704. https://doi.org/10.18632/oncotarget.2296
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 31, 2014 |
Publication Date | Jan 1, 2014 |
Deposit Date | Oct 26, 2017 |
Publisher | Impact Journals |
Peer Reviewed | Peer Reviewed |
Volume | 5 |
Issue | 17 |
Pages | 7691–7704 |
DOI | https://doi.org/10.18632/oncotarget.2296 |
Public URL | https://nottingham-repository.worktribe.com/output/1110199 |
Publisher URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202154/ |
You might also like
Highly electron deficient diketopyrrolopyrroles
(2023)
Journal Article
In Vitro Anticancer Properties of Novel Bis-Triazoles
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search